Fund managers have forecast an M&A boom for the biotech sector following Donald Trump's win in the US Presidential Election, but have warned of future uncertainty for wider healthcare services companies in areas such as Obamacare.
In the 24 hours following the US election result, healthcare and biotech-focused investment trusts rebounded after facing significant headwinds in the run-up to the vote, as the Nasdaq Biotechnology index...
Political fears in Europe and UK
Attracting and supporting the industry's best women
Slow progress in improving diversity
Best-performing fund over five years